by Peter Ciszewski | Aug 23, 2018
The U.S. Food and Drug Administration approved cenegermin (Oxervate), for the treatment of neurotrophic keratitis, a rare disease affecting the cornea (the clear layer that covers the colored portion of the front of the eye). This is the first approved drug for this...
by Peter Ciszewski | Aug 21, 2018
Editor’s Note: This interview was conducted at #Bio2018. Please pardon the background noise. Brian Schwartz, Chief Medical Officer of ArQule, discusses his company and it’s focus on disease management. ArQule is engaged in the research and...
by Peter Ciszewski | Aug 17, 2018
Luca Santarelli, MD of Therachon discusses his company’s lead pipeline candidate, TA-46, a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Achondroplasia is an autosomal dominant disorder...
by Peter Ciszewski | Aug 16, 2018
The U.S. Food and Drug Administration (FDA) has approved ivacaftor (KALYDECO) to be used in children with cystic fibrosis ages under the age of 2 years old who have at least 1 mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene that is...
by Peter Ciszewski | Aug 15, 2018
Vanessa Vogel-Farley, Executive Director, Dup15q Alliance discusses her Alliance and some of the research for Dup15q syndrome, the common name for chromosome 15q11.2-q13.1 duplication syndrome. Dup15q syndrome is the common name for chromosome 15q11.2-q13.1...
